ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 907

Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis

Liana Fraenkel1, Charles Cunningham2, Gillian A. Hawker3 and Lisa Suter4, 1Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 2McMaster University, Hamilton, ON, Canada, 3Women's College Research Institute, University of Toronto, Toronto, ON, Canada, 4Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: DMOAD and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Considerable efforts are currently being directed at developing robust and efficient trial designs to study the efficacy of disease modifying drugs (DMOADs) for osteoarthritis (OA). As part of this effort, an understanding of patients’ preferences is needed.

Methods: We administered a conjoint analysis survey to a convenience sample of 304 patients attending outpatient clinics. The survey was composed of 4 attributes each having 3 levels: (1) administration (pill, injection (SC), infusion (IV)), (2) benefit (prevents progression in 40%, 60%, or 80%), (3) risk (mild: < 1 week and reversible, moderate: (1-2 weeks and requires treatment, serious: requires hospitalization), and (4) cost (easy, somewhat, hard to afford). All subjects were provided with a detailed description of each attribute before performing the survey. The survey included 12 choice tasks each with 3 medications and a “None” option (Figure). We performed Latent Class Segmentation analysis and simulations to estimate preferences for 4 options: Best Case (pill, prevents progression in 80%, mild side effects, easy to afford), Worst Case (IV, prevents progression in 40%, serious side effects, hard to afford), SC (SC, prevents progression in 40%, moderate risk, somewhat hard to afford), IV (same as previous except IV).

Results: 304 subjects participated; median (range) age=57 (34-89); 55% female; 69% Caucasian, 45% employed; 37% college graduates; 29% reported knee pain often or very often; 30% reported physician diagnosed knee arthritis. Segmentation analysis revealed 4 distinct groups of patients. The relative importances of the attributes are presented in Table 1. Treatment preferences are described in Table 2. Group 1 (5%) do not want to perform injections and only consider DMOADs under the Best Case scenario; Group 2 (19.4%) are most influenced by risk and fewer prefer DMOADs under more realistic scenarios; Group 3 (16.4%) consistently reject DMOADs, and Group 4 (59.2%) strongly prefer DMOADs regardless of risk or cost.

Conclusion: Almost 60% of patients surveyed are willing to accept substantial risk in order to prevent progression of OA. These findings should help inform future drug development.

Description: C:Userslf57DesktopDMOAD Figure.gif

Table 1. Relative Importances of Each Attribute

Attribute

Group 1

(N=15)

Group 2

(N=59)

Group 3

(N=50)

Group 4

(N=180)

1. Administration

58.5

11.5

11.8

2.9

2. Benefit

12.1

22.9

27.5

50.5

3. Risk

14.6

35.7

28.5

24.6

4. Cost

14.8

29.8

32.2

22.1

Table 2. Percent Preferring Each Hypothetical Treatment Option

Scenario

Group 1

(N=15)

Group 2

(N=59)

Group 3

(N=50)

Group 4

(N=180)

Best case

99.4

98.2

18.4

89.8

Worst case

0.7

4.4

7.6

85.4

SC

5.3

67.2

12.4

86.3

IV

20.2

54.9

11.1

86.1


Disclosure:

L. Fraenkel,
None;

C. Cunningham,
None;

G. A. Hawker,
None;

L. Suter,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-patient-preferences-to-inform-the-development-of-disease-modifying-drugs-for-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology